Filing Analysis
Indaptus Therapeutics announced its quarterly financial results for the period ending June 30, 2026, and reported the outcomes of its 2026 annual meeting of stockholders.
📋 Key Facts
- Quarterly earnings release issued on August 13, 2026, for the quarter ended June 30, 2026.
- Annual Meeting held on August 10, 2026, with a high quorum of approximately 96.75% (109,556,567 shares present).
- Three Class II directors (David Natan, Tim Ruan, and Dr. Johnny Fox Arrowsmith) were elected to terms expiring in 2029.
- Stockholders ratified the appointment of Haskell & White LLP as independent auditors for fiscal year 2026.
- The 2026 Equity Incentive Plan was approved by shareholders.
Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement on June 17, 2026, to issue 20,000,000 shares of common stock at $0.60 per share to non-U.S. accredited investors. The private placement raised approximately $12,000,000 in gross proceeds.
🚩 Red Flags
- Significant dilution: Issuance of 20 million shares at a low price point ($0.60) suggests potential downward pressure on share price upon registration.
- Registration requirement: The company is obligated to file a registration statement within 90 days, which will likely lead to increased selling pressure in the public market.
📋 Key Facts
- Date of Agreement: June 17, 2026
- Total shares issued: 20,000,000 common stock
- Price per share: $0.60
- Aggregate gross proceeds: ~$12,000,000 (before expenses)
- The offering represents less than 20% of the Company's issued and outstanding Common Stock.
- Purchasers are non-U.S. accredited investors participating via Regulation S.
Indaptus Therapeutics entered into a $6 million securities purchase agreement with David E. Lazar, resulting in significant control shifts and massive potential dilution. The deal includes provisions for a reverse stock split and the appointment of new management/board members.
🚩 Red Flags
- Extreme dilution: The conversion of preferred stock could result in 111 million new common shares, vastly exceeding current float/market cap context.
- Mandatory reverse stock split: The agreement requires a special meeting to vote on a reverse stock split (range TBD).
- Change in control/Management overhaul: Two directors resigned and David Lazar was appointed Chairman and Co-CEO immediately following the offering.
- Right of first refusal for investor: Investor has a right to purchase up to 25% of any new equity offerings during a six-month participation period.
📋 Key Facts
- David E. Lazar to purchase 300,000 shares of Series AA Preferred Stock and 700,000 shares of Series AAA Preferred Stock at $6.00 per share.
- Total aggregate gross proceeds: $6.0 million.
- Series AA converts into 20 shares of common stock per share; Series AAA converts into 150 shares of common stock per share.
- Potential total dilution from conversion: 111,000,000 shares of Common Stock.
- The agreement mandates a special meeting to address several items including a reverse stock split and increasing authorized shares.
- David E. Lazar appointed as Chairman of the Board and Co-CEO.
Indaptus Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a placeholder for the earnings press release issued on November 12, 2025.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Indaptus Therapeutics, Inc. filed an 8-K to announce a press release regarding clinical trial updates for its INDP-D101 program. The filing serves as a placeholder to incorporate the press release by reference.
📋 Key Facts
- The company issued a press release on September 4, 2025, regarding updates for the ongoing INDP-D101 clinical trial.
- The announcement is filed under Item 8.01 (Other Events).
- No financial data or material changes to corporate structure were disclosed in this specific filing text.
Indaptus Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- The company announced financial results for the fiscal quarter ending June 30, 2025.
- The announcement was made via a press release dated August 13, 2025.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
Indaptus Therapeutics completed the conversion of $5.7 million in convertible promissory notes into common stock and issued various warrants to investors and a placement agent. Shareholders also approved the issuance of these securities, including those related to a company director/CEO.
🚩 Red Flags
- Significant dilution: Conversion of notes into over 500k shares plus issuance of millions of warrants.
- Deep discount conversion: The $8.3024 price represents a 20% discount to the Nasdaq average.
- Related-party transaction: Proposal 2 specifically addressed the issuance of securities to the CEO/Director, which was approved by shareholders.
📋 Key Facts
- Private placement total gross proceeds: approximately $5.7 million (closed June 12 and June 30, 2025).
- Notes converted on July 27, 2025, into 545,598 shares of common stock.
- Conversion price set at $8.3024 per share (80% of the 5-day average Nasdaq closing price).
- Issued 1,384,722 warrants to Purchasers with an expiration date of July 27, 2030.
- Issued 83,083 Placement Agent Warrants to Paulson Investment Company, Inc. and designees.
- Shareholders approved the issuance of securities under Nasdaq Listing Rules 5635(c) and 5635(d).
- Quorum for special meeting was reached with 41.35% of outstanding Common Stock present.
Indaptus Therapeutics, Inc. has regained compliance with Nasdaq's minimum bid price requirement. The company successfully met the $1.00 per share threshold for 10 consecutive business days, resolving a deficiency that threatened its listing on the Nasdaq Capital Market.
🚩 Red Flags
- Historical non-compliance with minimum bid price requirements (though currently resolved).
📋 Key Facts
- Company was previously notified of non-compliance with Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price requirements.
- The compliance deadline to regain status was July 30, 2025.
- Nasdaq confirmed the company met the $1.00 per share requirement for 10 consecutive business days from June 27, 2025, to July 11, 2025.
- The bid price deficiency matter is now considered closed by Nasdaq.
Indaptus Therapeutics completed a second closing of a private placement of convertible promissory notes and warrants, bringing the total offering amount to approximately $5.7 million. The financing includes highly dilutive terms, including a 200% warrant coverage for purchasers upon stockholder approval.
🚩 Red Flags
- Highly dilutive financing structure (200% warrant coverage).
- Conversion trigger linked to an upcoming reverse split (expected July 27, 2025), suggesting imminent share consolidation.
- Need for special stockholder meeting to bypass Nasdaq Rule 5635(d) issuance limits, indicating potential dilution concerns.
- Significant placement agent compensation (12% cash fee + warrants).
📋 Key Facts
- Total aggregate principal amount of Notes: ~$5.7 million (comprising an initial $2.3M from June 12 and $3.4M from June 30).
- Notes bear interest at 6% per year and mature on July 28, 2026.
- Conversion price is set at a 20% discount (80%) to the 5-day VWAP, with a cap of $11.20.
- Purchasers receive warrants for an additional number of shares equal to 200% of the Conversion Shares upon stockholder approval.
- A special stockholder meeting is scheduled for July 25, 2025, to seek approval for issuances that may exceed Nasdaq limits.
- Paulson Investment Company, LLC served as placement agent with a 12.0% cash fee and additional warrants.
Indaptus Therapeutics, Inc. has implemented a 1-for-28 reverse stock split effective as of June 26, 2025. The action was approved by stockholders during the annual meeting held on June 10, 2025.
🚩 Red Flags
- Reverse stock split (typically used to boost share price to meet exchange listing requirements)
📋 Key Facts
- Reverse stock split ratio: 1-for-28
- Effective date: June 26, 2025, at 5:00 p.m. ET
- New CUSIP number for common stock: 45339J 204
- Trading on a split-adjusted basis begins June 27, 2025, on Nasdaq Capital Market
- Fractional shares will be settled via cash payments based on the closing price on June 26, 2025
- The split applies to all issued and outstanding common stock, options, and warrants
Indaptus Therapeutics entered into a $2.3 million private placement of convertible promissory notes and warrants to fund R&D and clinical trials. The deal includes highly dilutive terms, including a conversion price tied to a significant discount and a potential trigger based on an upcoming reverse stock split.
🚩 Red Flags
- Highly dilutive financing structure (convertible notes at a deep discount).
- Conversion trigger explicitly mentions a 'reverse split,' suggesting the company is anticipating or requiring one for Nasdaq compliance.
- The 80% conversion price mechanism creates significant downward pressure on stock price and immediate dilution upon conversion.
- Potential for massive share overhang via warrants (200% coverage if subscribed early).
- Significant placement agent compensation (12% cash fee + additional warrants).
📋 Key Facts
- Total principal amount of convertible promissory notes: $2.3 million.
- Notes bear 6% interest per annum and mature on July 28, 2026.
- Conversion price is set at 80% of the average Nasdaq closing price for the five trading days preceding conversion, capped at $0.40/share.
- Conversion trigger includes a date 30 days after the effectiveness of a reverse stock split.
- Warrants issued to purchasers are exercisable at the Conversion Price and expire in 5 years.
- Paulson Investment Company, LLC served as placement agent with a 12.0% cash fee plus warrants equal to 12.0% of conversion shares.
Indaptus Therapeutics held its Annual Meeting on June 10, 2025, where shareholders approved a proposed reverse stock split with a ratio ranging from 1-for-5 to 1-for-28. The meeting also resulted in the election of three Class I directors and the ratification of the company's independent auditor.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1-for-28) is often used to regain compliance with minimum bid price requirements for Nasdaq listing.
📋 Key Facts
- Annual Meeting held on June 10, 2025; 52% of outstanding common stock represented (8,386,348 shares).
- Proposal 4: Shareholders approved a reverse stock split with a ratio between 1-for-5 and 1-for-28.
- Proposal 1: Election of Mark J. Gilbert, Hila Karah, and Robert E. Martell, M.D., Ph.D. as Class I directors.
- Proposal 2: Ratification of Haskell & White LLP as independent auditor for fiscal year ending Dec 31, 2025.
- Proposal 3: Advisory approval of executive compensation was granted.
Indaptus Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of the release of quarterly earnings via press release.
📋 Key Facts
- The company announced financial results for the fiscal quarter ending March 31, 2025.
- The announcement was made on May 14, 2025.
- Financial results were released via a press release attached as Exhibit 99.1.
Indaptus Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 13, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing serves to furnish the press release containing financial results (Exhibit 99.1).
Indaptus Therapeutics entered into a $20 million Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing for the sale of common stock at a significant discount to market price. The company also terminated its existing purchase agreement with Lincoln Park Capital Fund, LLC.
🚩 Red Flags
- Highly dilutive financing structure (SEPA) typical of companies facing liquidity constraints.
- Significant discount to market price (3% below VWAP) facilitates immediate downward pressure on stock price upon issuance.
- Replacement of one predatory lender (Lincoln Park Capital) with another (Yorkville) suggests ongoing capital needs and potential 'death spiral' mechanics.
📋 Key Facts
- Entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (Yorkville) on February 12, 2025.
- The agreement allows for the sale of up to $20 million in common stock over a 36-month period.
- Shares will be purchased at 97% of the lowest of three consecutive daily VWAPs.
- Yorkville receives 305,960 shares as consideration and a $25,000 structuring fee.
- Includes an 'Exchange Cap' limiting issuances to 19.99% of outstanding shares unless stockholder approval is obtained or specific price thresholds are met.
- The company terminated its previous purchase agreement with Lincoln Park Capital Fund, LLC effective February 12, 2025.
Indaptus Therapeutics, Inc. received a notification from Nasdaq stating it is non-compliant with the minimum bid price requirement of $1.00 per share. The company has 180 days to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price requirement.
- Explicit mention of potentially implementing a reverse stock split to regain compliance (Red Flag Escalator).
- Stock has traded below $1.00 for 30 consecutive business days.
📋 Key Facts
- Received Notification Letter from Nasdaq on January 31, 2025.
- Non-compliance is due to failure to maintain a minimum bid price of $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
- The company has 180 calendar days, until July 30, 2025, to regain compliance.
- To cure the deficiency, the stock must close at or above $1.00 for 10 consecutive business days.
- Potential for an additional 180-day second compliance period if certain market value requirements are met.
Indaptus Therapeutics entered into a private placement agreement to raise $2.25 million through the issuance of common stock and warrants. The offering includes significant warrant coverage and requires the company to register these shares for resale within 60 days.
🚩 Red Flags
- Significant warrant overhang: The issuance of warrants equal to the number of shares issued (1:1 ratio) will result in substantial dilution upon exercise.
- Cash-less exercise feature: Warrants allow holders to receive a net number of shares instead of cash, which can lead to rapid share dilution without immediate capital inflow.
- High cost of capital: The 7% placement agent fee and additional warrants for the agent increase the total cost of the financing.
📋 Key Facts
- Aggregate gross proceeds: $2,246,500
- Issuance of 2,109,383 shares of common stock and 2,109,383 warrants.
- Combined price for one share and one warrant: $1.065 per unit.
- Warrant exercise price: $0.94 per share.
- Paulson Investment Company, LLC acting as exclusive placement agent with a 7.0% cash fee plus $25,000 in expenses.
- Placement agent received warrants for up to 147,656 shares at an exercise price of $1.175.
Indaptus Therapeutics announced a registered direct offering and private placement of 1,817,017 shares of common stock and an equal number of warrants. The deal includes significant dilution via warrant coverage and involves the company's CEO as a participant.
🚩 Red Flags
- Significant dilution: The issuance of warrants equal to the number of shares (1:1 warrant coverage) creates substantial potential dilution.
- Related-party transaction: The CEO is a purchaser in this offering.
- High cost of capital: 7.0% cash fee plus expenses and additional placement agent warrants increase the effective cost of the raise.
📋 Key Facts
- Total issuance: 1,817,017 shares of common stock and 1,817,017 warrants.
- Combined price for one share and one warrant: $1.175 per unit.
- Warrant exercise price: $1.05 per share.
- The CEO is participating in the offering, purchasing 42,553 shares and warrants.
- Paulson Investment Company, LLC acting as exclusive placement agent with a 7.0% cash fee plus $25,000 expenses.
- Placement Agent Warrants issued to Paulson for 124,212 shares at an exercise price of $1.3125.
Indaptus Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting date: November 12, 2024.
- Period covered: Quarter ended September 30, 2024.
Indaptus Therapeutics entered into a clinical supply agreement with BeiGene Switzerland GmbH to evaluate the combination of its product candidate, Decoy20, with BeiGene's anti-PD-1 antibody, tislelizumab. The study aims to treat patients with advanced solid tumors and is expected to begin in 2025 following FDA approval.
🚩 Red Flags
- Forward-looking statements explicitly mention 'conditions and events that raise substantial doubt regarding our ability to continue as going concern'.
- Explicitly mentions the need for additional capital due to lack of current cash flow.
- High research and development expenses noted in risk factors.
📋 Key Facts
- Agreement entered into on October 17, 2024, with BeiGene Switzerland GmbH.
- The partnership focuses on a Combination Study of Decoy20 and tislelizumab (BeiGene Product).
- Indaptus will pay all study costs except for the cost of the BeiGene Product.
- BeiGene will supply the anti-PD-1 antibody; Indaptus will supply Decoy20.
- The Combination Study is anticipated to begin in 2025, pending FDA approval.
Indaptus Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing serves to furnish the quarterly press release as Exhibit 99.1.
Indaptus Therapeutics, Inc. announced a registered direct offering and a private placement of common stock and warrants on August 7, 2024. The deal includes participation from the company's CEO and involves significant warrant issuance that will lead to future dilution.
🚩 Red Flags
- Significant potential dilution due to the issuance of warrants equal in number to the shares being offered.
- Related-party transaction: The CEO is a participant in the securities offering (Affiliate Securities).
- High placement agent fee of 9.0% plus expenses, which is substantial for a micro-cap company.
📋 Key Facts
- Registered direct offering of 1,643,837 shares of common stock.
- Private placement of warrants to purchase 1,643,837 shares of common stock.
- Combined price for one share and one warrant is $1.825 per unit.
- Warrant exercise price is set at $1.70 per share.
- The CEO participated in the offering, purchasing 84,932 shares and warrants.
- Paulson Investment Company, LLC acted as the exclusive placement agent with a 9.0% cash fee plus $50,000 in expenses.
- Warrants are immediately exercisable and expire in five years.
Indaptus Therapeutics, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 6, 2024. The meeting resulted in the election of three Class III directors and the approval of two key proposals regarding auditor ratification and a stock incentive plan.
📋 Key Facts
- Annual Meeting held on June 6, 2024, with approximately 50.09% of outstanding Common Stock represented (4,277,437 shares).
- Election of Roger J. Pomerantz, Michael J. Newman, and Jeffrey A. Meckler as Class III directors.
- Ratification of Haskell & White LLP as the independent registered public accounting firm for fiscal year 2024.
- Approval of the amendment and restatement of the 2021 Stock Incentive Plan, which includes increasing available shares and extending the evergreen provision.
Indaptus Therapeutics announced the successful advancement of its Phase I trial for Decoy20, specifically noting that the first patient has been dosed in the multi-dose portion following a Safety Review Committee evaluation. The company plans to present clinical data at the upcoming ASCO annual meeting.
🚩 Red Flags
- Forward-looking statements include explicit mention of 'conditions and events that raise substantial doubt regarding our ability to continue as going concern' and the need for additional capital due to lack of cash flow.
📋 Key Facts
- Successful advancement of Phase I trial investigating Decoy20.
- Safety Review Committee reviewed initial clinical data and approved progression.
- First patient has been dosed in the multi-dose portion of the study.
- The primary goal is to evaluate the safety of repeated administration of Decoy20.
- Company intends to move into combination studies with a checkpoint inhibitor.
Indaptus Therapeutics, Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Report date: May 8, 2024.
- Reporting period: Quarter ended March 31, 2024.
- The full press release is provided as Exhibit 99.1.
Indaptus Therapeutics announced that its Chief Scientific Officer will present new data regarding the research compound Decoy10 at the 2024 AACR Annual Meeting. The presentation focuses on confirming the mechanism of action for the company's proprietary platform technology.
🚩 Red Flags
- Forward-looking statements include a standard disclaimer regarding 'substantial doubt regarding our ability to continue as going concern' due to lack of cash flow (though this is boilerplate in the risk factors section).
📋 Key Facts
- Dr. Michael Newman (Founder and CSO) to present poster at 2024 AACR Annual Meeting in San Diego on April 10, 2024.
- Data concerns research compound Decoy10.
- The data aims to confirm the mechanism of action for the company's platform technology involving attenuated/killed non-pathogenic bacteria.
- Reported data suggests activation of multiple immune cell types including M1 macrophages, NK cells, dendritic cells, Th1 CD4, and CD8 T cells.
Indaptus Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 13, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- The information is furnished rather than filed under Section 18 of the Exchange Act.
Indaptus Therapeutics announced positive clinical results from the second cohort of its Phase 1 INDP-D101 trial for its lead compound, Decoy20. An independent Safety Review Committee recommended continuing the trial with multiple dosing schedules.
🚩 Red Flags
- Forward-looking statements include explicit mention of 'conditions and events that raise substantial doubt regarding our ability to continue as going concern' in the risk disclosures.
- Mention of the need for, and ability to raise, additional capital due to lack of current cash flow.
📋 Key Facts
- Positive results reported from the second cohort of Phase 1 INDP-D101 trial of lead compound Decoy20.
- Patients exhibited a broad immune response similar to the first cohort.
- Independent Safety Review Committee recommended continuing the trial and enrolling patients for multiple doses.
- The next stage aims to determine safety of multi-dosing and examine efficacy across multiple cancer types.
Indaptus Therapeutics, Inc. has amended and restated its bylaws to align with new SEC universal proxy rules and streamline stockholder nomination procedures.
📋 Key Facts
- The Board of Directors approved the Amended and Restated Bylaws on January 22, 2024.
- Amendments address compliance with SEC Rule 14a-19 (universal proxy rules).
- New bylaws require additional background information/disclosures for proposing stockholders and nominees.
- Prohibits submitting more director nominees than the number of directors up for election.
- Requires stockholders soliciting proxies to use a non-white proxy card color.
- Establishes federal district courts as the exclusive forum for certain Securities Act actions.